🔎 Trials Near Me

Home › Overweight › NCT07770841

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

RecruitingPhase 3

Efficacy and Safety of Once Daily Oral Semaglutide in Adults With Overweight or Obesity

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
* Female or male (sex at birth).
* Age 18 years or above at the time of signing the informed consent.
* Body mass index (BMI) of

  1. ≥ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease.

     OR
  2. ≥ 30.0 kg/m\^2.
* History of at least one self-reported unsuccessful dietary effort to lose body weight.

Exclusion Criteria:

* A self-reported change in body weight greater than (\>) 5% within 90 days before screening irrespective of medical records.
* HbA1c ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening.
* Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1/gastric inhibitory peptide RAs, or amylin analogues before screening. Consistent use is defined as treatment.

About the study

The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.

What is being tested

Sponsor: Novo Nordisk A/S · Participants: 450 · Started: Aug 12, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07770841

Locations in the U.S.

AlabamaUni of Alabama at Birmingham, Birmingham
CaliforniaHeadlands Research California, LLC, Escondido
National Research Institute - Huntington Park, Huntington Park
Los Angeles Institute for Metabolic Research, Los Angeles
FloridaERG Holding Company, LLC / Evolution Research Group, LLC, Delray Beach
ERG Holding Company, LLC / Evolution Research Group, LLC, Fort Myers
Jedidiah Clinical Research, Tampa
HawaiiEast West Med Res Inst, Honolulu
KentuckyL-MARC Research Center, Louisville
MissouriStudyMetrix Research LLC, City of Saint Peters
NevadaJubilee Clinical Research, Inc., Las Vegas
OregonCorvallis Clinic PC Clinical Research Department, Corvallis
PennsylvaniaUPA Ctr Weight and Eating Dis, Philadelphia (Not yet recruiting)
South CarolinaSpartanburg Medical Research, Spartanburg
TexasCedar Health Research, Dallas
VirginiaSelma Medical Associates, Winchester

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.